Cost of treating rare genetic blindness: $425,000 per eye

Treatment of a rare, inherited form of blindness will cost $425,000 per eye, the company bringing the therapy to market announced on Wednesday.
Source: Health News - UPI.com - Category: Consumer Health News Source Type: news

Related Links:

Publication date: Available online 24 May 2018 Source:Asian Journal of Pharmaceutical Sciences Author(s): Yumei Wu, Yuanyuan Liu, Xinyue Li, Dereje Kebebe, Bing Zhang, Jing Ren, Jun Lu, Jiawei Li, Shouying Du, Zhidong Liu Blindness and vision impairment are the most devastating global health problems resulting in a substantial economic and social burden. Delivery of drug to particular parts of the anterior or posterior segment has been a major challenge due to various protective barriers and elimination mechanisms associated with the unique anatomical and physiological nature of the ocular system. Drug administration to t...
Source: Asian Journal of Pharmaceutical Sciences - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 24 May 2018 Source:Diabetes & Metabolic Syndrome: Clinical Research & Reviews Author(s): Md. Badrul Alam Miah, Mohammad Abu Yousuf Millions of people in Bangladesh and the world have a metabolic disease named diabetes. It is also responsible for occurring different kinds of diseases such as heart attack, kidney disease, blindness and renal failure. Diabetes is a deadly, disabling disease whose risk is increasing at an alarming rate day by day perspective to Bangladesh. The detection process of diabetes is a tedious and multilayered task from some important risk factors. Like othe...
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - Category: Endocrinology Source Type: research
Electric cataracts: a cause of bilateral blindness in Kashmir, Published online: 23 May 2018; doi:10.1038/s41433-018-0128-xElectric cataracts: a cause of bilateral blindness in Kashmir
Source: Eye - Category: Opthalmology Authors: Source Type: research
In this report, we also provide a detailed review of previously reported cases with B3GALNT2-related dystroglycanopathy and compare them to our reported child. In addition, we study the genotype–phenotype correlation in these cases. [...] Georg Thieme Verlag KG Stuttgart · New YorkArticle in Thieme eJournals: Table of contents  |  Abstract  |  Full text
Source: Neuropediatrics - Category: Neurology Authors: Tags: Original Article Source Type: research
Authors: Lahola-Chomiak AA, Walter MA Abstract We explore the ideas and advances surrounding the genetic basis of pigment dispersion syndrome (PDS) and pigmentary glaucoma (PG). As PG is the leading cause of nontraumatic blindness in young adults and current tailored interventions have proven ineffective, a better understanding of the underlying causes of PDS, PG, and their relationship is essential. Despite PDS being a subclinical disease, a large proportion of patients progress to PG with associated vision loss. Decades of research have supported a genetic component both for PDS and conversion to PG. We review th...
Source: Journal of Ophthalmology - Category: Opthalmology Tags: J Ophthalmol Source Type: research
CONCLUSION: There are neither standardized etiological assessment nor clear diagnostic and therapeutic protocols for children. TNFα inhibitors are more effective in controlling inflammation in severe pediatric uveitis. PMID: 29778284 [PubMed - as supplied by publisher]
Source: Journal Francais d Ophtalmologie - Category: Opthalmology Tags: J Fr Ophtalmol Source Type: research
Authors: Bidot S, Biotti D Abstract Transient monocular blindness is an acute episode of ischemic origin in which one eye has profound visual loss, followed by full recovery within one hour. Transient monocular blindness most often occurs in the setting of retinal ischemia secondary to carotid embolism, but other mechanisms have been reported, including thrombosis (most often in the setting of giant cell arteritis), hemodynamic disorders (secondary to severe carotid stenosis) or vasospasm. Transient monocular blindness is considered a transient ischemic attack originating in the carotid arteries and must benefit fr...
Source: Journal Francais d Ophtalmologie - Category: Opthalmology Tags: J Fr Ophtalmol Source Type: research
This article reviews evidence from the literature suggesting that primary open angle glaucoma (POAG) represents a group of heterogeneous diseases with varying clinical features rather than a single disease.Recent FindingsA growing body of evidence has been made available recently indicating that POAG behaves differently in different subpopulations. Although normal tension glaucoma has long been regarded as a diagnosis distinct from POAG, a considerable degree of overlap exists in their pathophysiology and clinical characteristics and suggests that intraocular pressure alone is not a reliable means of separating POAG into d...
Source: Current Ophthalmology Reports - Category: Opthalmology Source Type: research
The objective of this study was to measure the mean central corneal thickness of different sub types of glaucoma and ocular hypertension of patients attending Menelik Hospital.Participants and Methods: A cross sectional comparative hospital-based study was carried out at the glaucoma clinic of Menelik ΙΙ Hospital to assess the pattern of central corneal thickness of patients with different subtypes of glaucoma from 01 May 2014 to 30 August 2014. Central corneal thickness was determined by taking average of six measurements using ultrasonic Pachymetry. All consecutive open angle glaucoma patient s and age matched ...
Source: Ethiopian Journal of Health Development - Category: African Health Source Type: research
(Michigan State University) A Michigan State University veterinary ophthalmologist has modified a gene therapy that reverses blindness in dogs that have a certain form of a disease known as progressive retinal atrophy, or PRA, and is now looking to advance the treatment for human use. Simon Petersen-Jones in the College of Veterinary Medicine has received a five-year, $8.2 million grant from the National Institutes of Health to further the therapy for people who have a type of retinitis pigmentosa.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
More News: Blindness | Genetics | Health | Opthalmology